Back to Search Start Over

COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge.

Authors :
Bronstein Y
Gat R
Levi S
Cohen YC
Luttwak E
Benyamini N
Shragai T
Vitkon R
Neaman M
Eilaty N
Levi M
Trestman S
Perry C
Herishanu Y
Avivi I
Source :
Cancer cell [Cancer Cell] 2022 Jun 13; Vol. 40 (6), pp. 578-580. Date of Electronic Publication: 2022 Apr 21.
Publication Year :
2022

Abstract

Competing Interests: Declaration of interests Y.H. reports honoraria from Janssen, AbbVie, Roche, Astra-Zeneca, and Medision, not related to this study. I.A. reports speaker’s bureau for Gilead, Novartis, AbbVie, and Janssen and served as a consultant for Janssen, MSD, AbbVie, Novartis, and Roche, not related to this study. The other authors declare no competing interests.

Subjects

Subjects :
Humans
SARS-CoV-2
COVID-19

Details

Language :
English
ISSN :
1878-3686
Volume :
40
Issue :
6
Database :
MEDLINE
Journal :
Cancer cell
Publication Type :
Editorial & Opinion
Accession number :
35477028
Full Text :
https://doi.org/10.1016/j.ccell.2022.04.015